Teva Pharmaceuticals
Edit

Teva Pharmaceuticals

http://www.tevapharm.com/
Last activity: 15.09.2026
Active
Categories: ContentCorporateHealthTechInformationMedTechPageProductSocialSpecialtyWebsite
This Facebook page will be used for sharing company news and information about Teva Pharmaceuticals globally, managed by the Corporate Communications team on Teva’s behalf.
This Facebook page is primarily for discussing news, events, featured business activities as well as topics related to health and wellness. We are excited to interact with you on our social channels, and look forward to fruitful and engaging dialogue.
This is not a forum to discuss treatments or conditions, or as a venue for reporting adverse events or side effects. If you have a specific question about our products or services, please visit the Contact Us section of our corporate website: https://www.tevapharm.com/contact-us/

If you are reporting an adverse event or side effect relating to one of our products, please contact Safety.AE@teva.co.il or submit your information through the Contact Us section of our corporate website at https://www.tevapharm.com/contact-us/.

If you are having a life-threatening emergency, please contact your physician or seek local emergency assistance.

We welcome your interactions, and we’ll try to reply to questions in a timely manner. Due to the limitations of these social channels and the regulated nature of the pharmaceutical industry, our replies may be brief. When possible, we will try to direct you to additional relevant information or support.

Teva’s corporate social accounts will be regularly monitored and updated during business hours, Monday to Friday. Comments or questions posted outside of this time will be responded to as soon as possible during business hours. Social channels may occasionally be unavailable and we accept no responsibility for lack of service due to the channel platform’s downtime.

When interacting with Teva on social channels, we encourage you to be respectful and polite; and to avoid sharing fraudulent, personally identifying, or confidential content. We will not respond to foul language; disparaging, defamatory, or inflammatory comments; or topics unrelated to Teva, and we reserve the right to delete inappropriate comments from our page as necessary.

Disclaimers:
We cannot share specific information about our products; for product-related information, please visit the relevant country or product website or submit your question through our website: https://www.tevapharm.com/contact-us/

We cannot comment on or respond to issues related to legal and financial matters, regulatory issues, or proprietary information on social channels.

Our social accounts may provide links to independent third-party sites in posts and tweets. Teva has no way of controlling the content of the content of third-party sites, nor does Teva endorse, or is Teva responsible for, the content on third-party sites.
Teva does not endorse, and is not responsible for, the content of any social accounts that the Teva social accounts follow.
Likes
44.82K
Followers
807.22K
Website visits
125.1K /mo.
Mentions
165
Location: Israel, Tel Aviv District, Tel Aviv-Yafo
Employees: 10001+
Founded date: 1901

Investors 1

DateNameWebsite
-Thomas H. ...thl.com

Mentions in press and media 165

DateTitleDescription
20.09.2026AI Infrastructure Giant Temporal Secures $550M, Valuation Soars to $12.55 BillionTemporal secured $550 million in Series E funding. This propels its valuation to $12.55 billion. The capital will fuel global expansion and advanced research and development. Temporal's Durable Execution platform delivers critical reliabili...
15.09.2026Perk Brings Its Spend Platform to U.S.: NYSE Content UpdateNYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 15, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE ...
14.09.2026Temporal Raises $550 Million in Series E Round: NYSE Content UpdateNYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 14, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE ...
10.09.2026PW Consulting: Global Sedative-Hypnotic Drug Market Hits $4.85B in 2025, Projected 5.85% CAGR to 2032Navigating the Global Sedative-Hypnotic Drug Market: Strategic Imperatives for 2026 and Beyond The global healthcare landscape is undergoing a significant transformation, driven by an aging population, increasing prevalence of sleep disorde...
09.09.2026Беззвучный режимБеззвучный режим Что мешает борьбе с мигренью В России каждый пятый человек страдает мигренью — хроническим неврологическим заболеванием, которое проявляется приступами сильной, пульсирующей головной боли. Опросы показывают, что лишь до пол...
01.09.2026Sun Pharma signs deal with US government to reduce drug pricesDrug major Sun Pharmaceutical Industries has signed a deal with the US government to lower prices of its innovative drugs in the US, in line with the lowest prices paid by other developed nations, under the most favoured nation (MFN) pricin...
24.07.2026Trump's Generic Drug Tariffs: U.S. Onshoring Push Faces Steep ChallengesU.S. faces major generic drug tariff changes. Trump announced duties up to 200% on imported generics. A two-year window encourages domestic manufacturing. This policy aims to onshore critical drug production. Industry concerns are high. Gen...
22.07.2026Trump’s generic drug tariffs: What they could mean for medicine prices, manufacturers and supplyTrump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details r...
09.07.2026Immunotherapy Drugs Market to Reach $580.6 Billion by 2029The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te...
23.06.2026Clarivate Releases 2025 Sustainability ReportNew report highlights progress against goals and a decline in total carbon emissions LONDON, June 23, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released its 2025 Sustaina...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In